Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities.
about
Shared HLA class II-associated genetic susceptibility and resistance, related to the HLA-DQB1 gene, in IgA deficiency and common variable immunodeficiencyAnalysis of MHC class II DP, DQ and DR alleles in Crohn's diseaseInterferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosisThe retrovirus/superantigen hypothesis of multiple sclerosis.Identification of susceptibility genes for experimental autoimmune encephalomyelitis that overcome the effect of protective alleles at the eae2 locus.An immunogenetic heterogeneity in multiple sclerosis.Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical eventsHLA-DQ polymorphism influences progression of demyelination and neurologic deficits in a viral model of multiple sclerosisA transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.Multiple sclerosis complexity in selected populations: the challenge of Sardinia, insular Italy.Autoreactive T cells in multiple sclerosis.Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis.HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses.The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosisPolyreactive myelin oligodendrocyte glycoprotein antibodies: Implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis.Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis.Multiple sclerosis genetics: leaving no stone unturned.Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice.The relation between menarche and the age of first symptoms in a multiple sclerosis cohort.An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locusSoluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease.HLA class II susceptibility and resistance genes in patients with multiple sclerosis from northern Spain, by DNA-RFLP genotyping.HLA-DQ8 (DQB1*0302)-restricted Th17 cells exacerbate experimental autoimmune encephalomyelitis in HLA-DR3-transgenic mice.The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients.1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.HLA-DR and -DQ gene polymorphism in West Africans is twice as extensive as in north European Caucasians: evolutionary implications.Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers.Multiple sclerosis: individualized disease susceptibility and therapy response.Multiple sclerosis: multiple etiologies, multiple genes?Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis.Primary progressive multiple sclerosis: a distinct syndrome?Genetics of demyelinating diseases.Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitisThe natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.Demyelination versus remyelination in progressive multiple sclerosis.Genetic burden of common variants in progressive and bout-onset multiple sclerosis.
P2860
Q24563276-038897A5-B7BE-45A9-A855-B76D20FAE2EBQ24670577-FF5C6532-A726-4732-BB60-4AB74F8EAA50Q28272201-6DAE1DA0-2FAA-45E0-9040-DAC8437CFEFCQ30317136-2286892B-2D79-4DAD-ABB2-70752066B57FQ30781951-4EBDA5CE-27EA-4F53-B374-1EFC439BFB1BQ33591702-F8876EDC-DF5F-409A-8C2B-93F8873041AEQ33733828-0D33B48E-2AE4-47A9-873F-3D2B182C9859Q33745499-C8A66B94-6B0B-4FA9-A48B-904FB72D30C9Q33769952-D300F148-9FF8-44F0-A8F9-3E65F1498F77Q34722561-1C60661F-5489-40BD-9853-14DA65AE1E64Q35173092-F5A6EF6F-115C-48CC-B504-D4E63D2FB06FQ35179093-857FAF72-D26C-4999-972B-C68EC2967214Q35465548-47F74C7F-A8AB-44A6-8CD8-50B090DFB8DBQ35470638-07549693-A288-48F6-BD51-543179D67F18Q35487679-13F88A25-1554-436E-A7DC-32790D881559Q35691550-239AADAC-5C94-4C73-84E5-CBEA349E0369Q35745678-EAF3B13F-E0B3-4892-8827-52DDE4DD4B8CQ36171871-6CD1FA46-06DC-45EF-9798-BCA5B53C18C9Q36318089-13BD92B4-7035-4C08-9578-679DAD41FD0CQ36399873-ACEF9EE4-0783-479F-B63F-24511253D339Q36501521-C8CE4979-5EF0-44DE-B768-62322E1BF12EQ36693352-C91AAE2E-54D8-4D0A-A571-C7A66F73BCBBQ36885953-869C73AC-5C17-47E0-A671-D8EBBFC9456EQ36977214-8769EDF8-23E2-41D2-AD2B-B24300D782D4Q37151283-59CFD771-BA97-434C-B329-2DA8F1B0B3BAQ37191533-213218DE-DCBF-4DE7-9064-1CB9EA864F70Q37322604-04BC2E79-B1F9-45B8-A130-0644251EA1EBQ37369983-D3202FCD-9ACA-4615-AE63-BCB2BA31EE5FQ37597756-18B756BE-388A-4C7B-8BF1-F90721736659Q37990779-F0733603-7DCC-45AD-AAE3-C560B548A14DQ38079620-87EC3C74-44DC-430C-AF17-47209F2882CCQ40393845-12979A37-F070-4D13-8D2F-2DE616BA965EQ40437100-1016A935-36FA-4079-8A05-8F07B0AF9AC7Q40923764-D351F75C-EA7A-42F1-9769-FC6AE156C844Q41157673-3E8A6BE2-E18A-4800-93E2-3F8878395226Q42011739-63DACAF0-F345-4034-A6AE-3DD39B149465Q42082013-C100E6BF-D453-47DA-B408-F28A722BC949Q43462704-E2D88C9B-F2AF-4FA9-B01A-DD8A84B7AAD5Q44651982-1C7CDFBC-7768-4AE2-93C2-3F4D930CC4E2Q45381521-F157FE06-3D34-45F4-95A6-0FD0BDD7CD3C
P2860
Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities.
description
1989 nî lūn-bûn
@nan
1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Primarily chronic progressive ...... lly distinct disease entities.
@ast
Primarily chronic progressive ...... lly distinct disease entities.
@en
Primarily chronic progressive ...... lly distinct disease entities.
@nl
type
label
Primarily chronic progressive ...... lly distinct disease entities.
@ast
Primarily chronic progressive ...... lly distinct disease entities.
@en
Primarily chronic progressive ...... lly distinct disease entities.
@nl
prefLabel
Primarily chronic progressive ...... lly distinct disease entities.
@ast
Primarily chronic progressive ...... lly distinct disease entities.
@en
Primarily chronic progressive ...... lly distinct disease entities.
@nl
P2093
P2860
P356
P1476
Primarily chronic progressive ...... lly distinct disease entities.
@en
P2093
Carlsson B
Fredrikson S
Kam-Hansen S
P2860
P304
P356
10.1073/PNAS.86.18.7113
P407
P50
P577
1989-09-01T00:00:00Z